Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Journal Article

Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treatment of breast cancer. Thus, agents that reduce HER3 expression at the plasma membrane may synergize with current therapies and offer a novel therapeutic strategy to improve treatment.

Full Text

Duke Authors

Cited Authors

  • Ren, XR; Wang, J; Osada, T; Mook, RA; Morse, MA; Barak, LS; Lyerly, HK; Chen, W

Published Date

  • December 2015

Published In

Volume / Issue

  • 17 / 1

Start / End Page

  • 528 -

PubMed ID

  • 25778364

Pubmed Central ID

  • 25778364

Electronic International Standard Serial Number (EISSN)

  • 1465-542X

Digital Object Identifier (DOI)

  • 10.1186/s13058-015-0528-9


  • eng

Conference Location

  • England